• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    AnnoraPharma`s Generic Brivaracetam Receives Tentative Approval in the U.S

    FDA

    MSN Lab`s Generic Brivaracetam Receives Approval in the U.S.

    FDA

    MSN Laboratories` Generic Brivaracetam Receives Approval in the U.S.

    FDA

    Apotex`s Generic Brivaracetam Receives Approval in the U.S.

    FDA

    Aurobindo`s Generic Brivaracetam Receives Approval in the U.S.

    FDA

    Lupin`s Generic Brivaracetam Receives Approval in the U.S.

    FDA

    Zydus`s Generic Brivaracetam Receives Approval in the U.S.

    FDA

    Apotex`s Generic Brivaracetam Receives Tentative Approval in the U.S.

    FDA

    Positive MHRA decision for Briviact

    PHARMATIMES

    Aurobindo Pharma Limited Generic Brivaracetam Receives Approval in the U.S.

    FDA

    Sunshine Generic Brivaracetam Receives Approval in the U.S.

    FDA

    Mylan Labs Generic Brivaracetam Receives Approval in the U.S.

    FDA

    UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved

    PRNEWSWIRE

    Lupin receives US FDA tentative approval for generic Briviact tablets.

    PHARMABIZ

    Lupin Receives Tentative U.S. FDA Approval for Brivaracetam Tablets

    NDTV

    Zydus Cadila gets USFDA tentative nod for epilepsy treatment drug

    BUSINESS STANDARD

    Zydus Cadila receives tentative approval from USFDA for Brivaracetam Tablets

    BUSINESS STANDARD

    NATCO launches Brivaracetam tablets in India

    EXPRESS PHARMA

    Natco Pharma launches epilepsy treatment drug Brivaracetam in India

    ECONOMIC TIMES

    Health Canada Approves BRIVLERA® (brivaracetam) to treat partial-onset seizures

    NEWSWIRE

    FDA Confirms Paragraph IV Patent Challenge of Briviact 205836 (Brivaracetam) 10 mg, 25 mg, 50 mg, 75 mg and 100 mg

    FDA

    UCB Announces New Data from its Epilepsy Portfolio on the AmericanNeurology

    PRNEWSWIRE

    UCB Presents New Data Demonstrating Commitment to Epilepsy

    PR NEWSWIRE

    Copycats wanted: Pfizer, AZ and more under threat as China solicits generics

    FIERCE PHARMA

    UCB’s antiepileptic drug gains new US indication

    PMLIVE

    New indication for BRIVIACT brivaracetam, UCB`s newest antiepileptic drug approv

    PR NEWSWIRE

    UCB seeks USFDA approval for Briviact CV as monotherapy treatment patients

    PHARMABIZ

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.